In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research (MDPI - Multidisciplinary Digital Publishing Institute, 2023)
Keywords: 5-ALA; 68Ga-labelled carbon nanoparticles; 99mTc-FAP inhibitor; 99mTc-labeled iFAP; [3H]ifenprodil; [61Cu]Cu-DOTA-NOC; [61Cu]Cu-DOTA-TATE; [61Cu]Cu-DOTA-TOC; [68Ga]Ga-MAA; ABC-transporter; Alzheimer’s disease; amyloid-beta; animal model; astrocyte; biodistribution; Biology, life sciences; blood–brain barrier; copper-61; diabetes; drug development; drug-induced liver injury; extracellular vesicles (EVs); FAP; FDG; fluorescein; fluorescence guided surgery; fluorine-18; glioblastoma; GluN1/2B receptors; hepatotoxicity; heterobivalent peptide; high resolution; hybrid imaging; I-124; imaging; intra-arterial (I.A.) administration; intravenous (I.V.) administration; lipophilicity; liquid targets; liver function; magnetic resonance imaging; Mathematics and Science; metabolism; microglia; microvasculature imaging; multimodal imaging; n/a; nanoparticle; neurodegenerative diseases; neuroinflammation; neurotransmitter receptors; NIR-AZA; NMDA; organic anion-transporting polypeptide; oxime; PET; PET imaging; PET/CT; pharmacokinetics; photoacoustic; positron emission tomography; positron emission tomography (PET); post-processing; PSMA; psychiatric disorders; radiometals; receptor occupancy; Reference, Information and Interdisciplinary subjects; Research and information: general; SLC-transporter; SPECT; synaptic density; tumor microenvironment; umbilical cord mesenchymal stem cell (UCMSC); V/Q PET/CT; vascular imaging; σ1 and σ2 receptors